The major flu vaccine antigen, hemagglutinin, is shown. Colored in dark blue is a region of the vaccine that differs between the current egg-grown H3N2 vaccine strain and circulating H3N2 viral strains.
Credit: Zost et al, PNAS, 2017
PHILADELPHIA – The low efficacy of last year’s influenza vaccine can be attributed to a mutation in the H3N2 strain of the virus, a new study reports. Due to the mutation, most people receiving the egg-grown vaccine did not have immunity against H3N2 viruses that circulated last year, leaving the vaccine with only about 30 percent effectiveness. Scott Hensley, PhD, an associate professor of Microbiology, in the Perelman School of Medicine at the University of Pennsylvania, describes his team’s findings in the Proceedings of the National Academy of Sciences this week.
“Our experiments suggest that influenza virus antigens grown in systems other than eggs are more likely to elicit protective antibody responses against H3N2 viruses that are currently circulating,” Hensley said. “The 2017 vaccine that people are getting now has the same H3N2 strain as the 2016 vaccine, so this could be another difficult year if this season is dominated by H3N2 viruses again.”
Flu vaccines work by priming the immune system with purified proteins from the outer layer of killed flu viruses. This induces immune cells to make antibodies that stop foreign invaders from infecting cells, readying them to attack flu viruses when the body sees them again. Most flu vaccine proteins are purified from a virus grown in chicken eggs, although a small fraction of flu vaccine proteins are produced in systems that do not involve eggs.
During the 2014-2015 flu season, a strain of the H3N2 virus with a different outer layer protein emerged and this version of H3N2 remains prevalent today. The 2016-2017 seasonal flu vaccine was updated to include the new version of this protein; however, Hensley’s lab found that the egg-grown version of this protein acquired a new mutation. “Current H3N2 viruses do not grow well in chicken eggs, and it is impossible to grow these viruses in eggs without adaptive mutations,” Hensley said.
The team showed that antibodies elicited in ferrets and humans exposed to the egg-produced 2016-2017 strain did a poor job of neutralizing H3N2 viruses that circulated last year. However, antibodies elicited in ferrets infected with the current circulating H3N2 viral strain (that contains the new protein) and humans vaccinated with a H3N2 vaccine produced in a non-egg system were able to effectively recognize and neutralize the new H3N2 virus.
“Our data suggest that we should invest in new technologies that allow us to ramp up production of influenza vaccines that are not reliant on eggs,” Hensley said. “In the meantime, everyone should continue to get their annual flu vaccine. Some protection against H3N2 viruses is better than nothing and other components of the vaccine, like H1N1 and influenza B, will likely provide excellent protection this year.”
Coauthors are Seth J. Zost, Kaela Parkhouse, Megan E. Gumina, Kangchon Kim, Sebastian Diaz Perez, Patrick C. Wilson, John J. Treanor, Andrea J. Sant, and Sarah Cobey.
This work was funded in part by the National Institutes of Health (R01AI113047, R01AI108686, DP2AI117921, CEIRS HHSN272201400005C) and an Investigators in the Pathogenesis of Infectious Disease Award from the Burroughs Wellcome Fund.
Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, excellence in patient care, and community service. The organization consists of the University of Pennsylvania Health System and Penn’s Raymond and Ruth Perelman School of Medicine, founded in 1765 as the nation’s first medical school.
The Perelman School of Medicine is consistently among the nation's top recipients of funding from the National Institutes of Health, with $550 million awarded in the 2022 fiscal year. Home to a proud history of “firsts” in medicine, Penn Medicine teams have pioneered discoveries and innovations that have shaped modern medicine, including recent breakthroughs such as CAR T cell therapy for cancer and the mRNA technology used in COVID-19 vaccines.
The University of Pennsylvania Health System’s patient care facilities stretch from the Susquehanna River in Pennsylvania to the New Jersey shore. These include the Hospital of the University of Pennsylvania, Penn Presbyterian Medical Center, Chester County Hospital, Lancaster General Health, Penn Medicine Princeton Health, and Pennsylvania Hospital—the nation’s first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.
Penn Medicine is an $11.1 billion enterprise powered by more than 49,000 talented faculty and staff.